NeuroPace, Inc. (NPCE) is a Medical - Devices company in the Healthcare sector, currently trading at $15.35. It has a SharesGrow Score of 55/100, indicating a above average investment profile with 3 out of 7 criteria passed.
Analyst consensus target is NPCE = $19 (+23.8% upside).
Valuation: NPCE trades at a trailing Price-to-Earnings (P/E) of -22.2 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.52.
Financials: revenue is $100M, +30.3%/yr average growth. Net income is $21M (loss), growing at +25.6%/yr. Net profit margin is -21.5% (negative). Gross margin is 77.2% (+5.8 pp trend).
Balance sheet: total debt is $71M against $19M equity (Debt-to-Equity (D/E) ratio 3.72, leveraged). Current ratio is 5.28 (strong liquidity). Debt-to-assets is 67.1%. Total assets: $106M.
Analyst outlook: 9 / 10 analysts rate NPCE as buy (90%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 90/100 (Pass), Growth 100/100 (Pass), Past 0/100 (Fail), Health 33/100 (Fail), Moat 56/100 (Partial), Future 94/100 (Pass), Income 10/100 (Fail).
